Overview Desmopressin Acetate 0.2 mg Tablets, Fasting Status: Completed Trial end date: 2003-08-01 Target enrollment: Participant gender: Summary The objective of this study was to compare the single-dose relative bioavailability of TEVA and Aventis Pharmaceuticals (DDAVP®) 0.2 mg desmopressin acetate tablets following a 0.8 mg dose under fasting conditions. Phase: Phase 1 Details Lead Sponsor: Teva Pharmaceuticals USATreatments: Deamino Arginine Vasopressin